Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	5.6	9.59	1.95	0.37	1.06
Cash & Short-Term Investments	5.6	9.59	1.95	0.37	1.06
Cash Growth	-41.61%	392.10%	423.93%	-64.99%	-
Other Current Assets	0.66	0.64	2.35	0.41	0.42
Total Current Assets	6.26	10.23	4.3	0.79	1.48
Net Property, Plant & Equipment	2.46	3.8	5.34	1.09	-
Long-Term Investments	-	-	-	-	230.01
Other Long-Term Assets	0.14	0.15	0.37	0.73	0.28
Total Assets	8.86	14.18	10.02	2.6	231.77
Accounts Payable	0.02	0	2.88	2.27	0.06
Accrued Expenses	0.53	0.48	5.43	5.35	0.35
Short-Term Debt	-	-	-	1	-
Current Portion of Long-Term Debt	-	3.18	0.81	3.27	-
Current Portion of Leases	1.52	1.27	1.12	0.12	-
Other Current Liabilities	-	0.64	-	30.98	-
Total Current Liabilities	3.94	9.5	10.23	42.99	0.41
Long-Term Debt	0.6	0.6	2.06	-	-
Long-Term Leases	0.45	1.99	3.25	0.45	-
Other Long-Term Liabilities	0.12	0.13	2.71	-	16.04
Total Long-Term Liabilities	1.16	2.72	8.02	0.45	16.04
Total Liabilities	5.1	12.21	18.25	43.44	16.45
Common Stock	-	-	0	0	0
Additional Paid-in Capital	145.39	123.28	91.38	19.93	-
Accumulated Other Comprehensive Income	-0.01	-0.03	-0.05	-0.01	-
Retained Earnings	-141.62	-121.72	-99.57	-70.36	-14.69
Total Common Shareholders' Equity	3.76	1.53	-8.24	-50.44	-14.69
Minority Interest	-	0.43	-	9.6	230.01
Shareholders' Equity	3.76	1.97	-8.24	-40.84	215.32
Total Liabilities & Equity	8.86	14.18	10.02	2.6	231.77
Total Debt	2.56	7.04	7.24	4.84	0
Net Cash (Debt)	3.04	2.56	-5.29	-4.46	1.06
Net Cash Growth	18.83%	-	-	-	-
Net Cash Per Share	0.71	3.83	-37.50	-63.02	6.46
Book Value	3.76	1.53	-8.24	-50.44	-14.69
Book Value Per Share	0.87	2.30	-58.40	-712.09	-89.25
Tangible Book Value	3.76	1.53	-8.24	-50.44	-14.69
Tangible Book Value Per Share	0.87	2.30	-58.40	-712.09	-89.25

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q